Clinical Trial Results: Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating safety of alpelisib plus fulvestrant in men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer with PIK3CA…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Alpelisib (alpelisib)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced Breast Cancer | Phase 4 | Status: COMPLETED | Results posted: 2026-06-25